AI Article Synopsis
- Asthma is a chronic inflammatory disease affecting quality of life, and the Asthma Quality of Life Questionnaire (AQLQ) is a key tool for measuring patient-reported outcomes (PROs).
- A systematic review was conducted following PRISMA guidelines to assess long-term QoL outcomes related to omalizumab therapy in patients with moderate-to-severe allergic asthma, reviewing studies published until February 2018.
- Results from eight selected studies highlighted that omalizumab significantly improves both subjective and objective measures of asthma control over time, although the observational nature of these studies may introduce selection bias concerns.
Article Abstract
Background: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients' subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (AQLQ) is one of the main PROs among these.
Materials And Methods: To identify long-term asthma-related QoL outcomes associated with omalizumab therapy in patients with moderate-to-severe asthma, we developed a systematic review according to the PRISMA guidelines. Published real-world effectiveness studies of adults or adolescents (12 years or older) with moderate-to-severe allergic asthma treated with omalizumab for at least 48 weeks were reviewed. Sources used were Medline ( PubMed), the Cochrane Library and Google Scholar up to February 2018. In addition, a cross-referencing search was conducted to complete the revision.
Results: A total of 255 potential papers were identified in the first search through the database. After full-text viewing, eight articles were finally included in the review. We summarized the results according to the study design, patient baseline characteristics and effectiveness outcomes assessed by AQLQ score results: variation from baseline to the end of study. Results confirmed the long-term benefits of omalizumab as an add-on therapy in patients with uncontrolled moderate-to-severe allergic asthma. Since there is a lot of evidence on omalizumab effectiveness, we aimed to focus on how a therapy can change patient's QoL in a long time period. Data showed long-term effects of omalizumab treatment on subjective (PROs) and objective (lung function, corticosteroid use, hospitalizations, asthma exacerbation) effectiveness measures.
Conclusion: Studies included in our review were observational trials that, due to their design, present a potential risk of selection bias in the patients included. Beyond this limit, the evaluation of QoL using the AQLQ showed a clear increase over time, following both 48 weeks and 9 years of observation, where QoL improvements still were significant over baseline values.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492364 | PMC |
| http://dx.doi.org/10.1177/1753466619841350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases.
BMC Pulm Med
December 2024
Department of respiratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Background: Dupilumab inhibiting the signaling of interleukin(IL)-4 and IL-13 was recommended for the treatment of severe asthma in children ≥ 6 years old according to the Global Initiative for Asthma (GINA,2024).This study aimed to analyse the efficacy and safety of dupilumab in paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory disease in a real-world population.
Methods: We evaluated the medical records of paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory diseases, such as atopic dermatitis (AD) and allergic rhinitis (AR), receiving dupilumab treatment.
Efficacy and safety of 128 slice CT low-dose scanning technique combined with low-density contrast agent in computed tomography angiography of diabetic foot and lower limb.
Am J Transl Res
November 2024
Department of Medical Imaging, Shaanxi Kangfu Hospital No. 52, Electronic 2nd Road, Electronic City, Xi'an 710065, Shaanxi, China.
Objective: To evaluate the efficacy and safety of 128 slice CT low-dose scanning technology combined with low-density contrast agent in lower extremity computed tomography angiography (CTA) for patients with diabetic foot.
Methods: A retrospective study was conducted on 342 patients with diabetic foot admitted to Shaanxi Kangfu Hospital from March 2021 to May 2023. Of these, 181 received 128 slice CT low-dose scanning technology combined with low-density contrast medium for lower extremity CTA examination (research group), and 161 patients underwent conventional dose contrast medium for CTA examination (control group).
Insufficiency of Laboratory Data in Reflecting Allergic Rhinitis Severity Based on the Allergic Rhinitis and Its Impact on Asthma Guideline in Korean Patients.
J Rhinol
March 2024
Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background And Objectives: This retrospective study, conducted at a single tertiary medical center, aimed to investigate the correlation between the severity of allergic rhinitis (AR) based on subjective symptoms and the severity assessed through laboratory data.
Methods: In total, 584 patients who were diagnosed with AR by a multiple-allergen simultaneous test were included. Patients were classified into four groups according to the Allergic Rhinitis and its Impact on Asthma (ARIA) classification guideline.
Background: Allergic rhinitis (AR) affects up to 40% of the pediatric population. The US practice parameter recommends the use of INAH or INCS as first-line therapy for the treatment of AR. Although not directly targeted to children, the recent US Practice Parameters proposed intranasal antihistamines as first-line therapy whereas the ARIA guidelines did not.
View Article and Find Full Text PDFEfficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J).
Curr Med Res Opin
December 2024
Department of Dermatology, Dokkyo Medical University, Tochigi, Japan.
Article Synopsis
- The study aimed to assess the effectiveness and safety of lebrikizumab when combined with topical corticosteroids in Japanese patients aged 12 and older with moderate-to-severe atopic dermatitis (AD).
- Conducted over 16 weeks, the Phase 3 trial involved 286 participants who were randomly assigned to receive either lebrikizumab (administered every 2 or 4 weeks) or a placebo, with results showing significantly higher rates of improvement in skin condition among those receiving lebrikizumab.
- The treatment was found to have a good safety profile, with serious adverse events being rare, though some mild to moderate side effects were more common in the lebrikizumab groups compared to the placebo
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!